Exponent (EXPO) Q2 2026 earnings review
Accelerating Core Growth Validates the 'Physical AI' Thesis
Exponent delivered an exceptionally clean Q2, demonstrating that its core thesis—AI increasing the complexity of physical products—is translating directly into financial acceleration. Revenues Before Reimbursements (RBR) accelerated to 12% YoY growth ($148.9M), up from 10% in Q1. The Engineering segment, the company's profit engine, fired on all cylinders with 13% growth. Crucially, volume leverage is dropping to the bottom line, with EBITDA margins expanding 90 basis points to 28.7%. While cash depletion from aggressive stock buybacks warrants monitoring, management's decision to raise full-year guidance confirms strong visibility into H2 2026.
🐂 Bull Case
The proliferation of AI into hardware (consumer electronics, medical devices, automotive) is structurally raising the complexity of product failures. This is actively driving the 13% growth in the Engineering segment.
EBITDA margin expanded to 28.7% from 27.8% a year ago, proving the company can push high realized rate increases and leverage its fixed costs as utilization normalizes.
🐻 Bear Case
The reported 21% total revenue growth looks spectacular but is highly deceptive. It was inflated by a massive 150% YoY surge in zero-margin reimbursable expenses ($22.7M vs $9.1M).
Exponent has aggressively bought back $146.1M in stock in H1. As a result, cash and equivalents plummeted from $221.9M at year-end to just $66.6M, removing a significant layer of balance sheet flexibility.
⚖️ Verdict: 🟢
Bullish. The core growth trajectory is undeniably accelerating. The company's unique positioning at the intersection of complex physical engineering and emerging AI technology provides a durable moat. Margin expansion layered on top of double-digit top-line growth is a winning combination.
Key Themes
Engineering Segment Accelerating on AI Integration
The Engineering and Other Scientific segment, representing 85% of total RBR, is strongly accelerating. Growth hit 13% YoY in Q2, up from 12% in Q1 and flat performance a year ago. The driver is clear: user research studies and failure analysis are surging as clients embed AI into physical products (AR/VR form factors, health devices) and scale up physical data center infrastructure. Because failures in these physical AI systems are vastly more complex, Exponent's PhD-heavy talent pool is experiencing structural tailwinds.
Macro Infrastructure: The Grid Under Stress
As a secondary growth engine, the macro environment surrounding energy infrastructure is highly favorable. Exponent cited increased risk management and infrastructure-related engagements in the utility sector. The combination of intense new energy demands (AI data centers) and the need for resilient power against extreme weather continues to drive high-margin, proactive advisory work.
Environmental & Health Segment Reversing Upward
After a volatile FY25 where growth oscillated wildly (-4% in Q2, +9% in Q3, -5% in Q4, +2% in Q1), the Environmental & Health segment appears to be stabilizing and accelerating, posting 9% YoY growth in 26Q2. Management attributes this to engagements evaluating chemical impacts (like PFAS) on human health and the environment, indicating that complex global regulatory frameworks are forcing clients back to the table.
Total Revenue Growth Contradicts Underlying Reality
A casual glance at the income statement shows total revenue accelerating wildly by 21% YoY. However, this data point contradicts the reality of the core business. Net revenue (RBR) grew a solid but much lower 12%. The gap is entirely due to a 150% spike in Reimbursable Expenses, which jumped from $9.1M in 25Q2 to $22.8M in 26Q2. Because these are zero-margin pass-through costs (likely related to heavy physical testing materials or travel), they artificially inflate the top line without adding a single dollar to operating profit.
Rapid Cash Depletion via Capital Returns
Management's aggressive capital return strategy is dramatically shrinking the balance sheet. In just six months, cash and cash equivalents fell from $221.9M (Jan 2026) to $66.6M (Jul 2026). The company spent $146.1M on buybacks and $31.3M on dividends in H1 alone. While signaling immense board confidence (backed by a fresh $50M authorization increase), this pace of cash burn is mathematically unsustainable over the long term without a massive injection of debt, changing the historically conservative risk profile of the balance sheet.
Sustained Margin Leverage
Operating leverage is functioning as designed. By holding headcount growth to a disciplined 4-5% (based on prior commentary) while realizing mid-single-digit rate increases and improving utilization, Exponent pushed its EBITDA margin to 28.7% in Q2, up from 27.8% last year. Gross compensation expenses only grew 3.2% YoY ($100.5M vs $97.4M), severely lagging the 12% RBR growth and allowing profit to flow cleanly to the bottom line.
Other KPIs
Accelerating. Grew 12% YoY, the fastest core growth rate the company has seen in over four quarters, beating the prior Q1 run rate of 10% and significantly outperforming the flat 0% growth seen in the same quarter last year.
Accelerating. Up 15% YoY from $0.52. This outpaces core revenue growth of 12%, aided by margin expansion and a lower share count (diluted shares fell from 51.5M to 48.9M YoY due to the aggressive H1 repurchase program).
Expanding. Represents 28.7% of RBR, compared to 27.8% in Q2 2025. This margin performance strongly supports the full-year raised guidance of 27.8% to 28.1%.
Guidance
Accelerating. Management raised this from prior guidance of 'high-single digits' (roughly 8%). Given H1 RBR grew 11%, this implies H2 growth will slightly decelerate into the 7-9% range due to tougher comps, but remains highly robust compared to FY25's low single-digit performance.
Stable/Expanding. Raised slightly from the lower bound (previously 27.6% - 28.1%). Given that H1 achieved 28.6%, the company is baking in expected seasonality or strategic hiring investments in H2 that will bring the full-year average down slightly.
Stable. Suggests continued strong momentum, though slightly decelerating from Q2's 12% peak. At the midpoint (9%), this implies Q3 RBR of approximately $149.4M.
Stable. Compares favorably to historical averages and shows management expects to maintain the pricing and utilization benefits captured in H1.
Key Questions
Explaining the Reimbursable Spike
Reimbursable expenses surged 150% year-over-year in Q2. What specific project types or client demands are driving this massive increase in pass-through costs, and should we expect this elevated run rate to continue into H2?
Limits of the Buyback Strategy
With cash and equivalents drawn down to $66.6 million following $146 million in H1 repurchases, has the company reached a comfortable floor for its operating cash balance? How should investors model the pace of buybacks moving forward given the newly added $50M authorization?
Environmental & Health Sustainability
The Environmental and Health segment reversed from sluggishness to 9% growth this quarter. Is this acceleration the result of a few large regulatory compliance mandates (like PFAS), or a broader, sustainable recovery in life sciences proactive consulting?